Product Information
ALISKIREN 300 MG TABLET is a generic product labeled by Endo USA Inc., priced at $5.8584 per EA under NDC 49884042511. Its NADAC has been published 385 times since May 22, 2019.
FDA first approved this application on Mar 22, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Endo USA Inc.NDC
49884042511
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ALISKIREN HEMIFUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA206665FDA Approved
3/22/2019
TE Code
AB
On Market Since
3/25/2019
Pharmacological Classes
Price Statistics
The NADAC for ALISKIREN 300 MG TABLET has been published 385 times since May 22, 2019, and over the history we have for it it has declined 21.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.8584 per EA |
|---|---|
| All-time high | $7.7118 (May 12, 2021) |
| All-time low | $4.4638 (Jun 19, 2024) |
| 52-week high | $5.8584 |
| 52-week low | $5.0809 |
| Median price | $6.4680 |
| Average price | $6.3479 |
| Largest weekly change | +26.9% (Jun 17, 2020) |
| Weeks tracked | 385 |
| Tracking since | May 22, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ALISKIREN market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Endo USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ALISKIREN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Renin Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALISKIREN 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ALISKIREN 300 MG TABLET, manufactured by Endo USA Inc., is $5.8584 per EA (NDC 49884042511), effective Sep 30, 2026.
How has the price of ALISKIREN 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for ALISKIREN 300 MG TABLET has declined 21.5%. It has been tracked across 385 weekly CMS publications since May 22, 2019.
What are the highest and lowest recorded NADAC prices for ALISKIREN 300 MG TABLET?
Since May 22, 2019, the NADAC for ALISKIREN 300 MG TABLET has ranged from a low of $4.4638 (Jun 19, 2024) to a high of $7.7118 (May 12, 2021), with a median of $6.4680 per EA.
Are there cheaper alternatives to ALISKIREN 300 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ALISKIREN 300 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ALISKIREN 300 MG TABLET?
ALISKIREN 300 MG TABLET (NDC 49884042511) is labeled by Endo USA Inc., and CMS classifies it as a generic product.